The DOI matches its Crossref record.
A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial
Open accessAbstract
BACKGROUND: West Nile virus (WNV) is a mosquito-borne flavivirus that can cause severe meningitis and encephalitis in infected individuals. We report the safety and immunogenicity of a WNV DNA vaccine in its first phase 1 human study. METHODS: A single-plasmid DNA vaccine encoding the premembrane and the envelope glycoproteins of the NY99 strain of WNV was evaluated in an open-label study in 15 healthy adults. Twelve subjects completed the 3-dose vaccination schedule, and all subjects completed 32 weeks of evaluation for safety and immunogenicity. The development of a vaccine-induced immune response was assessed by enzyme-linked immunosorbant assay, neutralization assays, intracelluar cytokine staining, and enzyme-linked immunospot assay. RESULTS: The vaccine was safe and well tolerated, with no significant adverse events. Vaccine-induced T cell and antibody responses were detected in the majority of subjects. Neutralizing antibody to WNV was detected in all subjects who completed the 3-dose vaccination schedule, at levels shown to be protective in studies of horses, an incidental natural host for WNV. CONCLUSIONS: Further assessment of this DNA platform for human immunization against WNV is warranted. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00106769 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kushnir, N., Streatfield, S. J., & Yusibov, V. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.083 · Cited by 587
Vaccine protection against Zika virus from Brazil
Larocca, R. A., Abbink, P., Peron, J. P. S., de A. Zanotto, P. M., Iampietro, M. J., Badamchi-Zadeh, A., Boyd, M., Ng’ang’a, D., Kirilova, M., Nityanandam, R., et al. (2016) · Nature · doi:10.1038/nature18952 · Cited by 505
DNA vaccines: an historical perspective and view to the future
Liu, M. A. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00980.x · Cited by 468
West Nile virus infection and immunity
Suthar, M. S., Diamond, M. S., & Gale Jr, M. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2950 · Cited by 430
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Liu, M. A. (2019) · Vaccines · doi:10.3390/vaccines7020037 · Cited by 427
Rapid development of a DNA vaccine for Zika virus
Dowd, K. A., Ko, S.-Y., Morabito, K. M., Yang, E. S., Pelc, R. S., DeMaso, C. R., Castilho, L. R., Abbink, P., Boyd, M., Nityanandam, R., et al. (2016) · Science · doi:10.1126/science.aai9137 · Cited by 396
Self-citationGaudinski, M. R., Houser, K. V., Morabito, K. M., Hu, Z., Yamshchikov, G., Rothwell, R. S., Berkowitz, N., Mendoza, F., Saunders, J. G., Novik, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33105-7 · Cited by 301
Self-citationMartin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.026 · Cited by 267
Self-citationBroadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype
Dowd, K. A., DeMaso, C. R., Pelc, R. S., Speer, S. D., Smith, A. R. Y., Goo, L., Platt, D. J., Mascola, J. R., Graham, B. S., Mulligan, M. J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.049 · Cited by 206
Self-citationMartinez-Lopez, A., Encinas, P., García-Valtanen, P., Gomez-Casado, E., Coll, J. M., & Estepa, A. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4403-7 · Cited by 9
Metadata
- Authors
- Martin, J. E., Pierson, T. C., Hubka, S., Rucker, S., Gordon, I. J., Enama, M. E., Andrews, C. A., Xu, Q., Davis, B. S., Nason, M., Fay, M., Koup, R. A., Roederer, M., Bailer, R. T., Gomez, P. L., Mascola, J. R., Chang, G. J., Nabel, G. J., Graham, B. S., & Vaccine Research Center 302 Study Team
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-12-15
- Volume
- 196
- Issue
- 12
- Pages
- 1732-1740
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2110487156
- Cited by
- 185
- References
- 0
- FWCI
- 16.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.